Chardan Capital Downgrades EyePoint to Neutral, Lowers Price Target to $5

Benzinga Newsdesk www.benzinga.com Negative 88.2%

Neg 88.2% Neu 0% Pos 0%

Chardan Capital analyst Andreas Argyrides downgrades EyePoint (NASDAQ:EYPT) from Buy to Neutral and lowers the price target from $65 to $5.